@docpook
Account based inAustralia
About this account
- Account based in
- Australia
- Connected via
- Web
Account-level information from X, not a live location or the device used for a specific post.
Medical Oncologist specialising in urological cancers at Monash Cancer Centre. Clinical trial investigator and prostate cancer translational researcher.
Joined November 2012
- Tweets290
- Following144
- Followers324
- Likes120
David Pook retweeted
Great to see @ANZUPtrials #UNICAB Study poster @ASCO #GU24 presented by @docpook. Well done to entire team for their ongoing hard work #kidneycancer #improvingoutcomes #BaCT @PeterMacCC @IpsenGroup @CancerAustralia @DrCraigGedye @Prof_IanD
KN-564 shows significant improvement in overall survival in RCC with 12m of adjuvant pembro with HR 0.62. Meanwhile the Nivo arm of CM-914 is negative. Unsure if this is due to differences in drug activity or just duration of treatment. #GU24 – at San Francisco, CA
David Pook retweeted
Delving into the ENZAMET trial: Radiographic progression in mHSPC may occur without PSA elevation, challenging conventional monitoring methods. The study underscores the complexity of disease progression. #ProstateCancer
@Prof_IanD @ChrisSweens1
@ASCO #GU24 @OncoAlert @urotoday @oncodaily @DrChoueiri @yekeduz_emre @sophia_kamran @BraunMDPhD @AmandaNizamMD @TiansterZhang @RCCadvocate @ShuchiGulati @RuchikaTalwarMD @DrKarineTawagi @neerajaiims @montypal @crisbergerot @DrRanaMcKay @Tilki_De @CParkMD @cdanicas @FabioSchutz78 @PGrivasMDPhD
David Pook retweeted
Great @ANZUPtrials poster @ASCO #GU24 Baseline disease characteristics of participants enrolled on #ENZARAD & #DASLHiCaP Congrats @niazi_Dr7 @ChrisSweens1 @DrPaulNguyen & Scott Williams @TrialsCentre @ThePCCTC @cancertrials_ie @CDNCancerTrials @MSKCancerCenter @AstellasUS @Bayer
CONTACT-02 Study showed improvement in rPFS in CRPC patients with soft tissue disease from 4.2m to 6.3m with Cabo/Atezo vs ARSI switch. Lots of questions about the ethics of randomising a patient with liver mets to ARSI switch. I would not be comfortable doing this. #GU24 – at San Francisco, CA
BrCAAway study reports 39m rPFS with Abi+Olap in mCRPC with HRD, 8.4m for Abi and 14m for Olap. Possible synergy but less than 1/3 of monotherapy pts crossed over. 50% of pts screened for HRD were +ve which is far higher than we see in clinic. #GU24 – at San Francisco, CA
David Pook retweeted
JUST IN: some news in metastatic bladder cancer combinations via @Reuters
reut.rs/46Gga8h reut.rs/46Gga8h
David Pook retweeted
Gem/cis & nivolumab achieves significant PFS & OS in 1st line UC . Maintenance avelumab = 25% ⬆️ in OS, but not all pts get there. Better disease control during the chemo phase and competitive OS HR will be attractive to patients. news.bms.com/news/corporate-…
David Pook retweeted
Pleased to share @TheLancetOncol LENVA-PEMBRO across RCC variant histologies: papillary RCC, unclRCC and chromophobe RCC … interim @myESMO #ESMO22 and final @ChungHanLee3 @ASCO #ASCO23
full text: authors.elsevier.com/a/1hP1c…
Thanks to all who change
rareRCC pts Tx! – at Paris, France
David Pook retweeted
Liz Liow presenting KRAB data (Australian real world kidney cancer data) @ANZUPtrials #ANZUP23 at best of the best oral abstract session @WEHI_research @DrDanielHeng
Mitch Lawrence explaining how high dose testosterone can be used to treat prostate cancer and how his team are investigating this in PDX models #ANZUP23
Laura Porter discussing tumour microenvironment manipulation with carboplatin to improve uptake of Lewis Y targeted CAR T cells into prostate tumours. Keeping the dream of effective immunotherapy in prostate cancer alive. #ANZUP23
David Pook retweeted
#ANZUP23 ASM is happening tomorrow! This is your final opportunity to register for the premier GU cancer meeting in the region. Secure your spot now at anzup.org.au/registration-2/. We look forward to seeing you at Melbourne Convention Centre.
David Pook retweeted
New to the #ANZUP23 ASM, The Perfect Pitch workshop is chaired by @_ShankarSiva and @ciaraconduit. It is designed to discuss how to pitch an idea and how to bring new concepts forward for idea development, which could potentially move on to a fully fledged clinical trial.
David Pook retweeted
Now online @CCR_AACR - Phase IB study ipatasertib plus rucaparib in mCR #prostatecancer post-NHA. No evidence of synergistic or additive antitumor activity. No clear signal of benefit in biomarker +ve populations either
My take: Still no role for targeting PI3K pathway in mCRPC
David Pook retweeted
Dr David Pook @docpook on hot topics from 2022: more is not always better, when more drugs does not mean better outcomes | Best of GU Evening Symposium | @ANZUPtrials @USANZUrology @ANZUNS_Urology
David Pook retweeted
Good to see insights on management of prostate cancer from Prof Lisa Hovarth, A/Prof Jeff Goh and @docpook.
